Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicagrel Pharmacokinetics and Pharmacodynamics with Omeprazole
NCT05651074Phase 1Unknown
- Sponsor
- Jiangsu Vcare PharmaTech Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vicagrel in acute coronary syndrome (ACS), sponsored by Jiangsu Vcare PharmaTech Co., Ltd. Primary endpoints: Inhibition of Platelet Aggregation at Day 2, Platelet Reactivity Index at Day 2 and 2 more. Status: unknown.
02
Drugs
vicagrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT05651074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651074.